

Nepal Support for Human Papillomavirus Vaccine (HPV) Demonstration Programme

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Vaccines grant number: 1516-NPL-19a-X Cash support grant number: 1516-NPL-24a-Y			
3. Date of Decision Letter: 17 December 2015			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: HPV Demonstration Programme			
6. Vaccine type: HPV			
7. Preferred product presentation and formulation of vaccine: HPV Bivalent, 2 doses per vial, LIQUID			
8. Programme duration¹: 2015 - 2016			
9. Programme budget (indicative): (subject to the terms of the Partnership Framework Agreement):			
	2015	2016	Total ²
HPV vaccines (US\$)	US\$154,000	US\$149,500	US\$303,500
Cash (US\$)	US\$199,000	US\$25,000	US\$224,000
Total Programme budget (US\$)	US\$353,000	US\$174,500	US\$527,500
10. Vaccine introduction grant: Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³			
<i>Vaccines:</i>			
Type of supplies to be purchased with Gavi funds in each year	2015	2016	
Number of HPV vaccines doses	35,300	32,100	
Number of AD syringes	35,300	31,800	
Number of safety boxes	400	350	
Annual Amounts (US\$)	US\$154,000	US\$149,500	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

Cash support:

Cash support by year	2015
Annual Amounts (US\$)	US\$199,000

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns: Not applicable

16. Documents to be delivered for future disbursements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts. Further details can be found in the HPV application guidelines.

Reports, documents and other deliverables	Due dates
1. A copy of the approval by the local ethics committee, <i>if a country determined that review and approval was required.</i>	As soon as they become available, and at the latest by end of Year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)
2. Three evaluation reports of the HPV vaccination demonstration programme: <ul style="list-style-type: none"> a. Post Introduction Evaluation (PIE) b. Coverage survey c. Costing analysis 	
3. A report of the assessment of adolescent health interventions, with conclusions about what interventions would be feasible for integration in Year 2. <ul style="list-style-type: none"> a. If an adolescent health intervention is identified for joint delivery with HPV vaccine, the report should describe the identified intervention, the modified plans for Year 2, and the steps required for implementation with the district(s) and staff involved. b. If NO adolescent health intervention is identified for joint delivery with HPV vaccine the report should mention the reason why not. 	
4. A summary of the activities completed and progress towards the development of a national cervical cancer prevention and control strategy.	
5. A financial and activity report of expenditures by the end of Year 1.	End of Year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)
6. If an adolescent health intervention is identified for joint delivery with HPV vaccine OR if the country substantially changed their delivery strategy:	End of Year 2 (the second year starts when the first dose of vaccine is administered to a new

<p>a. A new survey to measure the coverage of HPV vaccination and the coverage of the jointly delivered health intervention(s) and</p> <p>b. An updated micro-costing analysis of programme delivery costs.</p> <p>7. If NO adolescent health intervention is identified for joint delivery with HPV vaccine in Year 2: A summary report of Year 2 delivery of HPV vaccinations.</p> <p>8. A financial and activity report of expenditures in Year 2.</p> <p>9. A copy of the developed or revised national cervical cancer prevention and control strategy.</p>	<p>cohort, which is usually 12 months after the start of Year 1 and continues for twelve calendar months)</p>
<p>17. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>	
<p>18. Other conditions: Not applicable</p> <p>Country is reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.</p>	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
17 December 2015